{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:44:34Z","timestamp":1792424674120,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T00:00:00Z","timestamp":1378166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>Patients with chronic kidney disease (CKD) have increased risk of fractures, yet the optimal treatment is unknown. In secondary analyses of large randomized trials, bisphosphonates have been shown to improve bone mineral density and reduce fractures. However, bisphosphonates are currently not recommended in patients with advanced kidney disease due to concern about oversuppressing bone remodeling, which may increase the risk of developing arterial calcification. In the present study we used a naturally occurring rat model of CKD with secondary hyperparathyroidism, the Cy\/+ rat, and compared the efficacy of treatment with zoledronic acid, calcium given in water to simulate a phosphate binder, and the combination of calcium and zoledronic acid. Animals were treated beginning at 25 weeks of age (approximately 30% of normal renal function) and followed for 10 weeks. The results demonstrate that both zoledronic acid and calcium improved bone volume by micro\u2013computed tomography (\u00b5CT) and both equally suppressed the mineral apposition rate, bone formation rate, and mineralizing surface of trabecular bone. In contrast, only calcium treatment with or without zoledronic acid improved cortical porosity and cortical biomechanical properties (ultimate load and stiffness) and lowered parathyroid hormone (PTH). However, only calcium treatment led to the adverse effects of increased arterial calcification and fibroblast growth factor 23 (FGF23). These results suggest zoledronic acid may improve trabecular bone volume in CKD in the presence of secondary hyperparathyroidism, but does not benefit extraskeletal calcification or cortical biomechanical properties. Calcium effectively reduces PTH and benefits both cortical and trabecular bone yet increases the degree of extra skeletal calcification. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.2089","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T09:08:25Z","timestamp":1378199305000},"page":"902-910","source":"Crossref","is-referenced-by-count":74,"title":["A Comparison of Calcium to Zoledronic Acid for Improvement of Cortical Bone in an Animal Model of CKD"],"prefix":"10.1093","volume":"29","author":[{"given":"Sharon M","family":"Moe","sequence":"first","affiliation":[{"name":"Richard L. Roduebush Veterans Affairs Medical CenterIndianapolisINUSA"},{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal X","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologySchool of MedicineIndiana UniversityIndianapolisINUSA"},{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Vincent H","family":"Gattone","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologySchool of MedicineIndiana UniversityIndianapolisINUSA"},{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Organ","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologySchool of MedicineIndiana UniversityIndianapolisINUSA"},{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologySchool of MedicineIndiana UniversityIndianapolisINUSA"},{"name":"Department of Medicine, School of MedicineIndiana UniversityIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"issue":"11","key":"2024020318550151900_jbmr2089-bib-0001","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int."},{"issue":"6","key":"2024020318550151900_jbmr2089-bib-0002","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","article-title":"Chronic kidney disease and bone fracture: a growing concern","volume":"74","author":"Nickolas","year":"2008","journal-title":"Kidney Int."},{"issue":"8","key":"2024020318550151900_jbmr2089-bib-0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.2009121208","article-title":"Bone mass and microarchitecture in CKD patients with fracture","volume":"21","author":"Nickolas","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"2024020318550151900_jbmr2089-bib-0004","first-page":"115","article-title":"Osteoporosis in end-state renal disease","volume":"19","author":"Lindberg","year":"1999","journal-title":"Semin Nephrol."},{"issue":"12","key":"2024020318550151900_jbmr2089-bib-0005","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020318550151900_jbmr2089-bib-0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int."},{"issue":"4","key":"2024020318550151900_jbmr2089-bib-0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020318550151900_jbmr2089-bib-0008","first-page":"S1","article-title":"Clinical Practice Guidelines for the Management of CKD-MBD","volume":"76","author":"KDIGO","year":"2009","journal-title":"Kidney Int."},{"issue":"4","key":"2024020318550151900_jbmr2089-bib-0009","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00198-012-2103-x","article-title":"Skeletal effects of zoledronic acid in an animal model of chronic kidney disease","volume":"24","author":"Allen","year":"2013","journal-title":"Osteoporos Int."},{"issue":"2","key":"2024020318550151900_jbmr2089-bib-0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ki.2008.456","article-title":"A rat model of chronic kidney disease-mineral bone disorder","volume":"75","author":"Moe","year":"2009","journal-title":"Kidney Int."},{"issue":"11","key":"2024020318550151900_jbmr2089-bib-0011","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat","volume":"26","author":"Moe","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020318550151900_jbmr2089-bib-0012","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/ndt\/gfp078","article-title":"R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)","volume":"24","author":"Moe","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"2024020318550151900_jbmr2089-bib-0013","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.nano.2011.03.004","article-title":"Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes","volume":"7","author":"Marra","year":"2011","journal-title":"Nanomedicine."},{"key":"2024020318550151900_jbmr2089-bib-0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"9","key":"2024020318550151900_jbmr2089-bib-0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1600-0714.2012.01154.x","article-title":"Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition","volume":"41","author":"Patntirapong","year":"2012","journal-title":"J Oral Pathol Med."},{"issue":"6","key":"2024020318550151900_jbmr2089-bib-0016","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020318550151900_jbmr2089-bib-0017","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.2010121275","article-title":"Discriminants of prevalent fractures in chronic kidney disease","volume":"22","author":"Nickolas","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"2024020318550151900_jbmr2089-bib-0018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med."},{"issue":"4","key":"2024020318550151900_jbmr2089-bib-0019","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2014results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract."},{"issue":"18","key":"2024020318550151900_jbmr2089-bib-0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020318550151900_jbmr2089-bib-0021","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","article-title":"Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid","volume":"13","author":"Brown","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"18","key":"2024020318550151900_jbmr2089-bib-0022","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMe078192","article-title":"Zoledronic acid and secondary prevention of fractures","volume":"357","author":"Calis","year":"2007","journal-title":"N Engl J Med."},{"issue":"6","key":"2024020318550151900_jbmr2089-bib-0023","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ajcn\/86.5.1780","article-title":"Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials","volume":"86","author":"Bischoff-Ferrari","year":"2007","journal-title":"Am J Clin Nutr."},{"key":"2024020318550151900_jbmr2089-bib-0024","doi-asserted-by":"crossref","first-page":"c3691","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction,cardiovascular events: meta-analysis","volume":"341","author":"Bolland","year":"2010","journal-title":"BMJ."},{"issue":"1","key":"2024020318550151900_jbmr2089-bib-0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ki.1997.297","article-title":"The hyperparathyroidism of chronic renal failure: a disorder of growth","volume":"52","author":"Parfitt","year":"1997","journal-title":"Kidney Int."},{"issue":"6","key":"2024020318550151900_jbmr2089-bib-0026","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S8756-3282(02)00735-4","article-title":"Misconceptions (2): turnover is always higher in cancellous than in cortical bone","volume":"30","author":"Parfitt","year":"2002","journal-title":"Bone."},{"issue":"2","key":"2024020318550151900_jbmr2089-bib-0027","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2215\/CJN.04650512","article-title":"The case for routine parathyroid hormone monitoring","volume":"8","author":"Sprague","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"2024020318550151900_jbmr2089-bib-0028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semnephrol.2009.01.006","article-title":"A structural approach to skeletal fragility in chronic kidney disease","volume":"29","author":"Leonard","year":"2009","journal-title":"Semin Nephrol."},{"issue":"26","key":"2024020318550151900_jbmr2089-bib-0029","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"2024020318550151900_jbmr2089-bib-0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2006.12.006","article-title":"Prevention of aortic calcification by etidronate in the renal failure rat model","volume":"558","author":"Tamura","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2024020318550151900_jbmr2089-bib-0031","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","article-title":"Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption","volume":"21","author":"Price","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2024020318550151900_jbmr2089-bib-0032","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2008.646","article-title":"Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure","volume":"75","author":"Lomashvili","year":"2009","journal-title":"Kidney Int."},{"issue":"8","key":"2024020318550151900_jbmr2089-bib-0033","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2024020318550151900_jbmr2089-bib-0034","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2362.2006.01665.x","article-title":"Vascular calcification and renal osteodystrophy relationship in chronic kidney disease","volume":"36","author":"Moe","year":"2006","journal-title":"Eur J Clin Invest."},{"issue":"3","key":"2024020318550151900_jbmr2089-bib-0035","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.1994.342","article-title":"Evidence for abnormal calcium homeostasis in patients with adynamic bone disease","volume":"46","author":"Kurz","year":"1994","journal-title":"Kidney Int."},{"issue":"5","key":"2024020318550151900_jbmr2089-bib-0036","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3\u20134 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int."},{"issue":"7","key":"2024020318550151900_jbmr2089-bib-0037","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1681\/ASN.2011101006","article-title":"Calcium deficiency reduces circulating levels of FGF23","volume":"23","author":"Rodriguez-Ortiz","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"18","key":"2024020318550151900_jbmr2089-bib-0038","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation."},{"issue":"11","key":"2024020318550151900_jbmr2089-bib-0039","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."},{"issue":"4","key":"2024020318550151900_jbmr2089-bib-0040","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0272-6386(04)00937-0","article-title":"Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis","volume":"44","author":"Nitta","year":"2004","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"2024020318550151900_jbmr2089-bib-0041","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1526-0968.2004.00136.x","article-title":"Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients","volume":"8","author":"Hashiba","year":"2004","journal-title":"Ther Apher Dial."},{"issue":"3","key":"2024020318550151900_jbmr2089-bib-0042","doi-asserted-by":"crossref","first-page":"E310","DOI":"10.1152\/ajpendo.00460.2012","article-title":"Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo","volume":"304","author":"Quinn","year":"2013","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"1","key":"2024020318550151900_jbmr2089-bib-0043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am J Kidney Dis."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2089","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/4\/902\/56566401\/jbmr2089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/4\/902\/56566401\/jbmr2089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:50:40Z","timestamp":1710327040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/29\/4\/902-910\/7599031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,3]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,9,3]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2089","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4,1]]},"published":{"date-parts":[[2013,9,3]]}}}